Financière de Tubize SA (TUB)
Market Closed
12 Jun, 15:30
€
241. 80
+5.6
+2.3709%
€
8.93B Market Cap
34.05 P/E Ratio
0.97% Div Yield
18,415 Volume
0 Eps
€ 236.2
Previous Close Want to track TUB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
TUB closed today higher at €241.8, an increase of 2.3709% from yesterday's close, completing a monthly increase of 23.4303% or €45.9. Over the past 12 months, TUB stock gained 15.1429%.
TUB is not paying dividends to its shareholders.
The last earnings report, released on Mar 21, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.7167%, based on the last three reports.
Financière de Tubize SA has completed 3 stock splits, with the recent split occurring on Jun 17, 2005.
The company's stock is traded on 8 different exchanges and in various currencies, with the primary listing on XMIL (EUR).
TUB Chart
Financière de Tubize SA (TUB) FAQ
What is the stock price today?
The current price is €241.80.
On which exchange is it traded?
Financière de Tubize SA is listed on XBRU.
What is its stock symbol?
The ticker symbol is TUB.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0.97%.
What is its market cap?
As of today, the market cap is 8.93B.
Has Financière de Tubize SA ever had a stock split?
Financière de Tubize SA had 3 splits and the recent split was on Jun 17, 2005.
Financière de Tubize SA Profile
| Biotechnology Industry | Healthcare Sector | Mr. Ahmed Khaled El-Hoshy CEO | XBRU Exchange | BE0003823409 ISIN |
| Belgium Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Financière de Tubize SA operates as a mono holding company primarily focused on the biopharmaceutical sector, through its significant investment in UCB, a leading biopharma company based in Belgium. This strategic position allows Financière de Tubize SA to leverage the innovations and financial performance of UCB, aiming for sustained growth and value creation in the biopharmaceutical industry. The company's operational and strategic base in Brussels, Belgium, places it at the heart of Europe's biopharmaceutical hub, enabling close collaboration and strategic alignment with UCB.
Products and Services
The principal product and service offering of Financière de Tubize SA is centered around its investment portfolio, with a key focus on:
- Investment in UCB - As a mono holding company, Financière de Tubize SA's primary product is its stake in UCB, a global biopharmaceutical company. This investment encompasses capital allocation towards UCB's research, development, and commercialization of innovative therapies in areas such as neurology and immunology. Through this stake, Financière de Tubize SA participates in the pharmaceutical industry's dynamics, including the development of drugs and treatment solutions aimed at addressing significant unmet medical needs.
Contact Information
Address: Allée de la Recherche 60
Phone: 32 4 9751 5208
Website: https://www.financiere-tubize.be
